ICON
Groningen, 9728 NZ, Netherlands
NCT Number: NCT05515588
The trial is intended to investigate the basic pharmacokinetics, excretion pathways and metabolism of BI 690517 and its metabolites.
Looking for future studies?
Notify Me18 year–55 year
Male
Interventional
Phase 1
Groningen, 9728 NZ, Netherlands
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Subjects will not be allowed to participate, if any of the following general criteria apply:
Further exclusion criteria apply.
BI 690517 (C-14)
Other names: Vicadrostat
BI 690517
Other names: Vicadrostat
Time frame: Up to 22 days.
Time frame: Up to 22 days.
Time frame: Up to 3 days.
Time frame: Up to 3 days.
Time frame: Up to 8 days.
Time frame: Up to 8 days.
Time frame: Up to 3 days.
Time frame: Up to 3 days.
Boehringer Ingelheim
Industry
A Phase I, Open-label Trial to Investigate Metabolism, Pharmacokinetics (Following a Mass Balance Design) and Absolute Bioavailability of BI 690517 (C-14) After Oral and Intravenous Administration in Healthy Male Subjects
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06068257
Breast Cancer, Breast Diseases
Orlando, Florida, United States
View Trial DetailsNCT06702423
Healthy
London, United Kingdom
View Trial DetailsNCT07223164
Healthy
Irvine, California, United States
View Trial DetailsNCT05595902
Healthy
Kadıköy, Istanbul, Turkey (Türkiye)
View Trial Details